Chong Kun Dang Pharmaceutical Corp. (KRX:185750)

South Korea · Delayed Price · Currency is KRW

64,200

+3,100 (5.07%)

Nov 5, 2026, 3:30 PM KST

Market Cap	845.90B -23.0%
Revenue (ttm)	1.78T +7.1%
Net Income	79.47B +30.3%
EPS	5,977.21 +29.3%
Shares Out	13.18M
PE Ratio	10.74
Forward PE	12.44
Dividend	500.00 (0.78%)
Ex-Dividend Date	Dec 29, 2025

Volume	34,820
Open	61,700
Previous Close	61,100
Day's Range	61,700 - 64,200
52-Week Range	59,600 - 98,100
Beta	0.21
Analysts	Buy
Price Target	102,857.14 (+60.21%)
Est. Earnings	Nov 9, 2026

About KRX:185750

Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in 1941 and is headquartered in Seoul, South Korea. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1941

Employees 2,170

Stock Exchange Korea Stock Exchange

Ticker Symbol 185750

Full Company Profile

Financial Performance

In 2025, KRX:185750's revenue was 1.69 trillion, an increase of 6.68% compared to the previous year's 1.59 trillion. Earnings were 77.51 billion, a decrease of -28.94%.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for 185750 stock is "Buy." The 12-month stock price target is ₩102,857, which is an increase of 60.21% from the latest price.

Price Target

₩102,857

(60.21% upside)

Analyst Consensus: Buy

Stock Forecasts